Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
COMMENTARY
Japan Needs Transparent Debates amid Growing “No” to Off-Year Revisions
Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision scheduled for FY2025 will be canceled, but its final text was revised from an earlier version to call for more…
To read the full story
Related Article
- PM Ishiba Takes Note of Opposition Party’s Plea for Scrapping Off-Year Revisions
December 9, 2024
- DPP Head, Industry Leaders United towards Stopping Off-Year Price Revisions
November 29, 2024
- DPP Confirms Plan to Urge 4 Ministers to Scrap Off-Year Price Revisions
November 28, 2024
- 3 Parties Reach Deal on Economic Plan, Off-Year “Abolition” Not Spelled Out
November 21, 2024
- DPP Leader Poised to Urge 4 Ministers to Abolish Off-Year Revisions
November 20, 2024
- DPP Prods Ruling Camp to Be More Specific on Off-Year Revision in Economic Plan
November 19, 2024
- LDP Broadly OKs Draft Economic Package, Adds Text on FY2025 Revision
November 15, 2024
- Draft Economic Package Embraces Measures to Ensure Stable Generic Supply
November 13, 2024
- DPP to Ruling Bloc: Quickly Scrap Off-Year Drug Price Revisions
November 13, 2024
- MHLW Eyes Extra Budget for Pharma Innovation, Generic Rejig
November 11, 2024
- Govt’s Council Calls for Pushing Drug Innovation, Generic Revamp
October 31, 2024
COMMENTARY
- Challenges in a Post-AG Era: Ensuring a Reliable Supply System
April 6, 2026
- Japan’s FY2026 R&D Tax Credit Reform Wins Broad Industry Backing
April 1, 2026
- A “Core Industry” in Name Only? Drug Pricing Reform Leaves a Sour Taste
March 24, 2026
- Beyond Elevidys: Next-Generation DMD Therapies Advance through Multiple Approaches
March 11, 2026
- Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause
March 10, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…